Showing 1 - 10 of 243,184
Persistent link: https://www.econbiz.de/10010336141
Persistent link: https://www.econbiz.de/10012807967
Persistent link: https://www.econbiz.de/10012494014
Life Years (QALYs), or aggregate Healthy Years Equiva- lent (HYEs), are usually criticized on equity grounds. We provide in … this paper normative justi_cations for alternative equity-sensitive models, such as the so-called models of mul …- tiplicative QALYs, multiplicative HYEs, and generalizations of the two. Our axiomatic approach assumes social preferences over …
Persistent link: https://www.econbiz.de/10011211882
Life Years (QALYs), or aggregate Healthy Years Equivalent (HYEs), are usually criticized on equity grounds. We provide in … this paper normative justifications for alternative equity-sensitive models, such as the so-called models of multiplicative … QALYs, multiplicative HYEs, and generalizations of the two. Our axiomatic approach assumes social preferences over …
Persistent link: https://www.econbiz.de/10011228293
The general issues of equity and efficiency are placed at the center of the analysis of resource allocation problems in …
Persistent link: https://www.econbiz.de/10005771928
The general issues of equity and efficiency are placed at the center of the analysis of resource allocation problems in …
Persistent link: https://www.econbiz.de/10005772085
Resources available to the health care sector are finite and typically insufficient to fulfil all the demands for health care in the population. Decisions must be made about which treatments to provide. Relatively little is known about the views of the general public regarding the principles...
Persistent link: https://www.econbiz.de/10011189693
The poorest nations of the world suffer from extreme disease burdens, which go largely untreated because weak incomes and the prevailing system of intellectual property rights fail to provide sufficient incentives to develop new treatments and distribute them at low cost. Recent price reductions...
Persistent link: https://www.econbiz.de/10010334779
We study the effects of parallel trade in the pharmaceutical industry. We develop a model in which an original manufacturer competes in its home market with parallel-importing firms. The theoretical analysis results in two key hypotheses. First, if the potential for parallel imports is...
Persistent link: https://www.econbiz.de/10010334916